Ernexa Therapeutics Inc. Income (Loss) from Continuing Operations before Income Taxes, Domestic
Ernexa Therapeutics Inc. (ERNA) reported Income (Loss) from Continuing Operations before Income Taxes, Domestic of -$14.13 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-13.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic · last filed 2026-03-13
- Ernexa Therapeutics Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2025 was -$14.13M.
- Ernexa Therapeutics Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2024 was -$44.53M.
- Ernexa Therapeutics Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2023 was -$21.65M.
- Ernexa Therapeutics Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2022 was -$24.51M.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month as first filed |
|---|---|---|
| 2025-12-31 | -$14.13M 10-K · filed 2026-03-13 | |
| 2024-12-31 | -$44.53M 10-K · filed 2026-03-13 | |
| 2023-12-31 | -$21.65M 10-K · filed 2025-03-12 | |
| 2022-12-31 | -$24.51M 10-K · filed 2024-03-14 | |
| 2021-12-31 | -$122.48M 10-K · filed 2023-03-20 | -$122.30M 10-K · filed 2022-04-15 |
| 2020-12-31 | -$7.29M 10-K/A · filed 2022-07-01 | -$26.53M 10-K · filed 2022-04-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |